Received May 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (DAPTACEL) | SANOFI PASTEUR | UNK | — | IM / RL |
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | UNK | — | IM / RL |
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | UNK | — | IM / LL |
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | UNK | W028534 | — |
No symptoms reported. No additional AE; administration of PEDVAX HIB after expiration date. HCP reports the PEDVAX HIB had an expiry date of 05/10/2025 and the expired vaccine was inadvertently administered to a patient on 05/13/2025; This spontaneous report was received from a Physician Assistant (medical assistant) and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions, concomitant therapies, past drug reactions and allergies were not reported. On 13-MAY-2025, the patient was inadvertently vaccinated with an expired dose of Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB), administered as prophylaxis (lot number W028534 has been verified to be valid for Haemophilus b Conjugate Vaccine [Meningococcal Protein Conjugate] [LIQUID PEDVAX HIB], expiration date 10-MAY-2025; dose, formulation, vaccination scheme frequency, anatomical site of injection and route of administration were not provided). The healthcare professional (HCP) reported that there was no temperature excursion (TE) for the administered vaccine, and that post expiry memo supported potency of the dose. No symptoms and no additional adverse event were reported for the patient. No further details.